Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 6/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.33 |
| ▸ | FAP | Q12884 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535268 | 1.00 | L3MBTL1 (0.38) | L3MBTL1HTTALDH1A1DPP4DPP8 | |
| SCHEMBL4035789 | 1.00 | L3MBTL1 (0.38) | L3MBTL1HTTALDH1A1DPP4DPP8 | |
| Ammonia Solution, Strong SCHEMBL9243093 | 0.98 | L3MBTL1 (0.37) | L3MBTL1HTTALDH1A1DPP4DPP8 | |
| SCHEMBL4202492 | 0.85 | L3MBTL1 (0.36) | L3MBTL1HTTALDH1A1DPP4DPP8 | |
| SCHEMBL12299850 | 0.83 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL12658782 | 0.83 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL12658780 | 0.83 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL23372707 | 0.79 | L3MBTL1 (0.38) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL21959058 | 0.79 | HTT (0.39) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL31474253 | 0.79 | L3MBTL1 (0.41) | L3MBTL1HTTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
| EP-1592389-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004071390-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | L3MBTL1 4633/4885HTT 3916/4885ALDH1A1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.